Merck Sharp & Dohme
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Merck Sharp & Dohme sits in the top decile of US sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count).
Merck Sharp & Dohme: 558 sponsored US clinical trials, 120 recruiting.
Merck Sharp & Dohme sponsors 558 registered US clinical trials on ClinicalTrials.gov, 120 of them currently recruiting, and 320 completed. 191 of these trials are in Phase 3-4 (later-stage) and 360 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 25 trials.
Top-decile sponsor footprint
Merck Sharp & Dohme ranks in the top decile of sponsors by registered trial count (#63 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
320 of 354 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
558 total, page 6 of 12
A Study of MK-1084 Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)
NCT06687759
A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)
NCT06295796
A Study of Diltiazem With a Single Dose of MK-6552 in Healthy Adult Participants (MK-6552-007)
NCT06662396
A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)
NCT06701305
A Study of the Effect of Itraconazole and Phenytoin on Calderasib (MK-1084) in Healthy Adults (MK-1084-008)
NCT06719557
A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Alendronate in Healthy Adult Participants (MK-0616-027)
NCT06772792
A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)
NCT06273774
A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026)
NCT06772779
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
NCT06285240
A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003)
NCT06619665
A Clinical Study of Enlicitide Decanoate (MK-0616) in Healthy Adult Participants (MK-0616-025)
NCT06691906
A Study of V330 in Healthy Younger (18 to 49 Years Inclusive) and Healthy Older (60 to 79 Years Inclusive) Participants (V330-001)
NCT06630117
Safety and Efficacy of MK-1200 in Participants With Advanced Solid Tumors (MK-1200-002)
NCT06242691
A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003)
NCT06692647
A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)
NCT06811246
Study of MK-6552 in Participants With Narcolepsy Type 1 (MK-6552-004)
NCT06179407
A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)
NCT06719570
A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)
NCT06699329
A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)
NCT06177912
A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)
NCT06619678
Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)
NCT06161116
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
NCT06113328
A Study of MK-2225 in Healthy Participants (MK-2225-003)
NCT06643390
A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)
NCT06052566
Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)
NCT06045507
A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)
NCT06699355
A Study of the Effect of Nemtabrutinib (MK-1026) on the Plasma Levels of Digoxin in Healthy Participants (MK-1026-012)
NCT06625827
A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)
NCT06688045
The Effect of Food and Water Volume in Healthy Adult Participants Administered Enlicitide Decanoate (MK-0616) (MK-0616-022)
NCT06658652
A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006)
NCT06703463
A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-017)
NCT06772818
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
NCT06036836
A Study to Evaluate the Effect of Food, Formulation, and a Proton Pump Inhibitor (PPI) on Calderasib (MK-1084) in Healthy Adult Participants (MK-1084-003)
NCT06619314
A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005)
NCT06665230
A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)
NCT06625840
A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)
NCT05953740
A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)
NCT06586671
A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)
NCT06783192
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids
NCT05952856
A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Heterozygous Familial Hypercholesterolemia (MK-0616-017/CORALreef HeFH)
NCT05952869
A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)
NCT06698016
A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-016)
NCT06772805
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Renal Impairment Study (MK-0616-020)
NCT05934292
A Study To Evaluate The Effect Of A Supratherapeutic Dose Of MK-8189 On The QTc Interval In Participants With Schizophrenia (MK-8189-019)
NCT05893862
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
NCT05877547
MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)
NCT06649877
A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)
NCT06658626
Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)
NCT05696080
A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)
NCT05656040
A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)
NCT06615869
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 230 |
| Phase 2 | 130 |
| Phase 3 | 173 |
| Phase 4 | 18 |
Therapeutic Areas
What is open in the Merck Sharp & Dohme pipeline
120 recruiting of 558 indexed (22% open); 320 completed (57%).
Phase mix: 191 late (III/IV) vs 360 early (I/II) (early-phase heavy).
Top condition: Healthy (25 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Merck Sharp & Dohme: open-pipeline peers nationwide
Peers matched on 558 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
Merck Sharp & Dohme sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 558 trials (± recruiting share)
- Amgen · 558 trials · 10% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
- University of Maryland, Baltimore · 560 trials · 18% recruiting
- Ohio State University · 552 trials · 21% recruiting
Sponsors near 22% open enrollment (± trial volume)
- AbbVie · 21% recruiting · 526 trials
- Women and Infants Hospital of Rhode Island · 22% recruiting · 65 trials
- Florida State University · 21% recruiting · 219 trials
- Axsome Therapeutics · 21% recruiting · 28 trials
Related
What to do with this Merck Sharp & Dohme page
558 registered trials is a research-attention snapshot, not an endorsement of Merck Sharp & Dohme or any single study.
- 120 of Merck Sharp & Dohme's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Merck Sharp & Dohme studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Merck Sharp & Dohme pipeline card: 558 registered trials from official public datasets.Report a data error.